We hypothesized that stimulating Toll-Like Receptor 2 (TLR2) on NK cells could modulate P-gp expression or activity, enhancing their resilience to cytotoxic drugs.<h4>Methods</h4>In this study, we first characterized NK cells from pediatric ALL patients, confirming the constitutive expression of both the therapeutic target (TLR2) and the drug efflux pump (P-gp) across all major subpopulations. The gene discussed is PGP; the disease is acute lymphoblastic leukemia.